Forty-four Years of the UK Prospective Diabetes Study: Legacy Effect and Beyond
Abstract
The results of the third phase of the UK Prospective Diabetes Study, recently published in The Lancet, reinforce the crucial role of early intensive glycaemic control in protection against micro- and macrovascular complications of diabetes. The benefits persist into the third decade after the completion of the trial, long after the difference in glycated haemoglobin between the intensive and standard arms has disappeared. This 'legacy effect' emphasizes the need for early diagnosis and aggressive management of diabetes from the time of its identification. It also validates the long-term safety and efficacy of conventional agents such as metformin and sulfonylureas. Understanding the mechanisms behind the 'legacy effect' could help target pathways that lead to the development of complications.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.